| Vol. 15.33 – 31 August, 2023 |
| |
|
|
| The combination of first-trimester human umbilical cord perivascular cells and endothelial colony forming cells synergistically reduced fibrosis and cardiomyocyte apoptosis, while promoting favorable cardiac remodeling and contractility. [NPJ Regenerative Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Syncytiotrophoblast-derived extracellular vesicles from preeclampsia placentas were collected by perfusion of placentas from women with preeclampsia and in vitro and ex vivo endothelial cell function were assessed. [Hypertension] |
|
|
|
| In vitro, A549 cells and primary human small airway epithelial cells were stimulated with LPS with or without human umbilical cord-derived MSC small extracellular vesicles treatment. [Journal Of Nanobiotechnology] |
|
|
|
| Scientists compared the safety and beneficial therapeutic effect of autologous bone marrow mononuclear cell versus allogeneic Wharton jelly-derived MSCs in diabetic patients with chronic limb-threatening ischemia. [Stem Cell Research & Therapy] |
|
|
|
| After analyzing the physical and biological properties of hyaluronic acid (HA) gel, human umbilical cord-derived MSCs-HA gel was applied in two in vivo models, and a molecular mechanism was investigated. [Stem Cells Translational Medicine] |
|
|
|
| The effects of human umbilical cord MSC-extracellular vesicles were assessed by measuring the microstructure of the femoral head using HE staining, micro-computed tomography, and TUNEL staining. [Food And Chemical Toxicology] |
| |
|
|
|
| The authors review the 2020–2022 PubMed literature database concerning the clinical efficacy of intravenous infusion-umbilical cord-MSCs among severe COVID-19 patients. [Stem Cells International] |
|
|
|
|
| Professor Kiss-Tóth and Professor Wilkinson are now jointly leading a preclinical program to test Stem CellX technologies for the development of a similar stem cell treatment in human patients. [University of Sheffield] |
|
|
|
|
| October 17 – 19, 2023 London, England, United Kingdom |
|
|
|
|
|
| Canadian Blood Services – Calgary, Alberta, Canada |
|
|
|
| Amgen – Burnaby, British Columbia, Canada |
|
|
|
| RareCyte – Seattle, Washington, United States |
|
|
|
| US FDA – Silver Spring, Maryland, United States |
|
|
|
| Friedrich Miescher Institute for Biomedical Research – Basel, Switzerland |
|
|
|
|